IPHA Stock: Why It Significantly Increased Today

By Amit Chowdhry ● Sep 17, 2021
  • The stock price of Innate Pharma SA (NASDAQ: IPHA) increased by over 30% pre-market. This is why it happened.

The stock price of Innate Pharma SA (NASDAQ: IPHA) increased by over 30% pre-market. Investors are responding positively to Innate Pharma announcing that AstraZeneca presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

The results of the interim analysis showed monalizumab in combination with durvalumab improved progression-free survival (PFS) and objective response rate (ORR) compared to durvalumab alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). And Monalizumab (Innate’s lead partnered asset) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.

Based on the results, AstraZeneca informed Innate that it plans to start a registrational study with monalizumab in combination with durvalumab in patients with unresectable, Stage III non-small cell lung cancer (NSCLC).

Stage III NSCLC:

Last year, an estimated 2.2 million people were diagnosed with lung cancer worldwide. Lung cancer is broadly split into NSCLC and small cell lung cancer with 80-85% classified as NSCLC. And Stage III NSCLC represents approximately one-quarter of NSCLC incidence.

Stage III (locally advanced) NSCLC is commonly divided into 3 subcategories (IIIA, IIIB, and IIIC), defined by how much the cancer has spread locally. And in contrast to Stage IV, when cancer has spread (metastasized), the majority of Stage III patients are currently treated with curative intent.

The majority of Stage III NSCLC patients are diagnosed with unresectable tumors.

KEY QUOTE:

“We’re pleased to see the monalizumab COAST results, particularly the improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer. Monalizumab is one of the first checkpoint inhibitors targeting a NK cell receptor, and today’s results further support the role it can play in treating certain cancers by blocking the inhibitory receptor, NKG2A. We look forward to continuing to invest in NK cell science and further advancing the next wave of scientific innovation at Innate.”

— Mondher Mahjoubi, Chief Executive Officer of Innate Pharma

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.